|
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
|
Dec 2016
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
|
Jan 2021
|
Therapeutic Advances in Hematology
|
myelodysplastic syndromes (MDS)
|
|
Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
|
Jan 2014
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
|
Treatment of low-risk myelodysplastic syndromes
|
Dec 2016
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
|
Jun 2015
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction
|
Jun 2023
|
SAGE Open Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Treatment of acquired aplastic anemia in children
|
Jan 2012
|
Hematology
|
aplastic anemia
|
|
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults
|
Nov 2012
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
|
Treatment and hematopoietic SCT in aplastic anemia
|
Nov 2012
|
Bone Marrow Transplant
|
aplastic anemia
|
|
Treating myelodysplastic syndromes: is more better?
|
Jan 2015
|
Lancet Haematol
|
myelodysplastic syndromes (MDS)
|
